Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

Published:2020-10-13 Issue:3 Volume:60 Page:365-378
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Badri Prajakta^ORCID,Jiang Xuemin,Borodovsky Anna,Najafian Nader,Kim Jae,Clausen Valerie A.,Goel Varun,Habtemariam Bahru,Robbie Gabriel J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-020-00940-9.pdf

Reference29 articles.

1. Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33(6):479–92.

2. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256–64.

3. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, et al. A status report on RNAi therapeutics. Silence. 2010;1(1):14.

4. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711–9.

5. Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol. 2004;8(6):570–9.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Merkel Cell Polyomavirus—Pathophysiology and Treatment in the Era of Gene‐Targeted Therapies;Reviews in Medical Virology;2024-09

2. The complement model disease paroxysmal nocturnal hemoglobinuria;European Journal of Immunology;2024-08-05

3. Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment;TRANSFUS MED HEMOTH;2024

4. Application of therapeutic nucleic acids and RNA interference to create products for personalised medicine;Biological Products. Prevention, Diagnosis, Treatment;2024-06-14

5. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials;Current Medical Research and Opinion;2024-05-16